David van Duin1, Cesar A Arias2, Lauren Komarow3, Liang Chen4, Blake M Hanson5, Gregory Weston6, Eric Cober7, Omai B Garner8, Jesse T Jacob9, Michael J Satlin10, Bettina C Fries11, Julia Garcia-Diaz12, Yohei Doi13, Sorabh Dhar14, Keith S Kaye15, Michelle Earley3, Andrea M Hujer16, Kristine M Hujer16, T Nicholas Domitrovic16, William C Shropshire17, An Dinh17, Claudia Manca4, Courtney L Luterbach18, Minggui Wang19, David L Paterson20, Ritu Banerjee21, Robin Patel22, Scott Evans3, Carol Hill23, Rebekka Arias23, Henry F Chambers24, Vance G Fowler25, Barry N Kreiswirth4, Robert A Bonomo26. 1. Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA. Electronic address: david_vanduin@med.unc.edu. 2. Division of Infectious Diseases and Center for Antimicrobial Resistance and Microbial Genomics, UTHealth, Houston, TX, USA; Center for Infectious Diseases, UTHealth, Houston, TX, USA; Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogota, Colombia. 3. The Biostatistics Center, The George Washington University, Rockville, MD, USA. 4. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA. 5. Division of Infectious Diseases and Center for Antimicrobial Resistance and Microbial Genomics, UTHealth, Houston, TX, USA; Center for Infectious Diseases, UTHealth, Houston, TX, USA. 6. Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. 7. Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH, USA. 8. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA. 9. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 10. Division of Infectious Diseases, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA. 11. Department of Medicine, Division of Infectious Diseases, Stony Brook University, Stony Brook, NY, USA. 12. Department of Infectious Diseases, Ochsner Clinic Foundation, New Orleans, LA, USA. 13. Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan. 14. Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, MI, USA. 15. Division of Infectious Diseases, University of Michigan, Ann Arbor, MI, USA. 16. Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA; Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 17. Division of Infectious Diseases and Center for Antimicrobial Resistance and Microbial Genomics, UTHealth, Houston, TX, USA. 18. Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA. 19. Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. 20. University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital Campus, QL, Australia. 21. Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA. 22. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, and Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA. 23. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA. 24. Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 25. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; Division of Infectious Diseases, Duke University, Durham, NC, USA. 26. Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA; Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, OH, USA; CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology, Cleveland, OH, USA.
Abstract
BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are a global threat. We aimed to describe the clinical and molecular characteristics of Centers for Disease Control and Prevention (CDC)-defined CRE in the USA. METHODS: CRACKLE-2 is a prospective, multicentre, cohort study. Patients hospitalised in 49 US hospitals, with clinical cultures positive for CDC-defined CRE between April 30, 2016, and Aug 31, 2017, were included. There was no age exclusion. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture. Clinical data and bacteria were collected, and whole genome sequencing was done. This trial is registered with ClinicalTrials.gov, number NCT03646227. FINDINGS: 1040 patients with unique isolates were included, 449 (43%) with infection and 591 (57%) with colonisation. The CDC-defined CRE admission rate was 57 per 100 000 admissions (95% CI 45-71). Three subsets of CDC-defined CRE were identified: carbapenemase-producing Enterobacterales (618 [59%] of 1040), non-carbapenemase-producing Enterobacterales (194 [19%]), and unconfirmed CRE (228 [22%]; initially reported as CRE, but susceptible to carbapenems in two central laboratories). Klebsiella pneumoniae carbapenemase-producing clonal group 258 K pneumoniae was the most common carbapenemase-producing Enterobacterales. In 449 patients with CDC-defined CRE infections, DOOR outcomes were not significantly different in patients with carbapenemase-producing Enterobacterales, non-carbapenemase-producing Enterobacterales, and unconfirmed CRE. At 30 days 107 (24%, 95% CI 20-28) of these patients had died. INTERPRETATION: Among patients with CDC-defined CRE, similar outcomes were observed among three subgroups, including the novel unconfirmed CRE group. CDC-defined CRE represent diverse bacteria, whose spread might not respond to interventions directed to carbapenemase-producing Enterobacterales. FUNDING: National Institutes of Health.
BACKGROUND:Carbapenem-resistant Enterobacterales (CRE) are a global threat. We aimed to describe the clinical and molecular characteristics of Centers for Disease Control and Prevention (CDC)-defined CRE in the USA. METHODS: CRACKLE-2 is a prospective, multicentre, cohort study. Patients hospitalised in 49 US hospitals, with clinical cultures positive for CDC-defined CRE between April 30, 2016, and Aug 31, 2017, were included. There was no age exclusion. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture. Clinical data and bacteria were collected, and whole genome sequencing was done. This trial is registered with ClinicalTrials.gov, number NCT03646227. FINDINGS: 1040 patients with unique isolates were included, 449 (43%) with infection and 591 (57%) with colonisation. The CDC-defined CRE admission rate was 57 per 100 000 admissions (95% CI 45-71). Three subsets of CDC-defined CRE were identified: carbapenemase-producing Enterobacterales (618 [59%] of 1040), non-carbapenemase-producing Enterobacterales (194 [19%]), and unconfirmed CRE (228 [22%]; initially reported as CRE, but susceptible to carbapenems in two central laboratories). Klebsiella pneumoniae carbapenemase-producing clonal group 258 K pneumoniae was the most common carbapenemase-producing Enterobacterales. In 449 patients with CDC-defined CRE infections, DOOR outcomes were not significantly different in patients with carbapenemase-producing Enterobacterales, non-carbapenemase-producing Enterobacterales, and unconfirmed CRE. At 30 days 107 (24%, 95% CI 20-28) of these patients had died. INTERPRETATION: Among patients with CDC-defined CRE, similar outcomes were observed among three subgroups, including the novel unconfirmed CRE group. CDC-defined CRE represent diverse bacteria, whose spread might not respond to interventions directed to carbapenemase-producing Enterobacterales. FUNDING: National Institutes of Health.
Authors: Belén Gutiérrez-Gutiérrez; Elena Salamanca; Marina de Cueto; Po-Ren Hsueh; Pierluigi Viale; José Ramón Paño-Pardo; Mario Venditti; Mario Tumbarello; George Daikos; Rafael Cantón; Yohei Doi; Felipe Francisco Tuon; Ilias Karaiskos; Elena Pérez-Nadales; Mitchell J Schwaber; Özlem Kurt Azap; Maria Souli; Emmanuel Roilides; Spyros Pournaras; Murat Akova; Federico Pérez; Joaquín Bermejo; Antonio Oliver; Manel Almela; Warren Lowman; Benito Almirante; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Alvaro Pascual; Jesús Rodríguez-Baño Journal: Lancet Infect Dis Date: 2017-04-22 Impact factor: 25.071
Authors: Ryan K Shields; Liang Chen; Shaoji Cheng; Kalyan D Chavda; Ellen G Press; Avin Snyder; Ruchi Pandey; Yohei Doi; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191
Authors: Manon R Haverkate; Martin C J Bootsma; Shayna Weiner; Donald Blom; Michael Y Lin; Karen Lolans; Nicholas M Moore; Rosie D Lyles; Robert A Weinstein; Marc J M Bonten; Mary K Hayden Journal: Infect Control Hosp Epidemiol Date: 2015-07-24 Impact factor: 3.254
Authors: Ana M Ocampo; Liang Chen; Astrid V Cienfuegos; Gustavo Roncancio; Kalyan D Chavda; Barry N Kreiswirth; J Natalia Jiménez Journal: Antimicrob Agents Chemother Date: 2015-10-26 Impact factor: 5.191
Authors: David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Patrick N A Harris; Paul A Tambyah; David C Lye; Yin Mo; Tau H Lee; Mesut Yilmaz; Thamer H Alenazi; Yaseen Arabi; Marco Falcone; Matteo Bassetti; Elda Righi; Benjamin A Rogers; Souha Kanj; Hasan Bhally; Jon Iredell; Marc Mendelson; Tom H Boyles; David Looke; Spiros Miyakis; Genevieve Walls; Mohammed Al Khamis; Ahmed Zikri; Amy Crowe; Paul Ingram; Nick Daneman; Paul Griffin; Eugene Athan; Penelope Lorenc; Peter Baker; Leah Roberts; Scott A Beatson; Anton Y Peleg; Tiffany Harris-Brown; David L Paterson Journal: JAMA Date: 2018-09-11 Impact factor: 56.272
Authors: Alexander Lawandi; Gleice C Leite; Matthew P Cheng; Brigitte Lefebvre; Jean Longtin; Todd C Lee Journal: Antimicrob Agents Chemother Date: 2021-03-18 Impact factor: 5.191
Authors: William C Shropshire; Samuel L Aitken; Reed Pifer; Jiwoong Kim; Micah M Bhatti; Xiqi Li; Awdhesh Kalia; Jessica Galloway-Peña; Pranoti Sahasrabhojane; Cesar A Arias; David E Greenberg; Blake M Hanson; Samuel A Shelburne Journal: J Antimicrob Chemother Date: 2021-01-19 Impact factor: 5.790
Authors: Ahmed Babiker; Lloyd G Clarke; Melissa Saul; Julie A Gealey; Cornelius J Clancy; M Hong Nguyen; Ryan K Shields Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079
Authors: Max W Adelman; Chris W Bower; Julian E Grass; Uzma A Ansari; Elizabeth A Soda; Isaac See; Joseph D Lutgring; Jesse T Jacob Journal: Open Forum Infect Dis Date: 2021-12-29 Impact factor: 3.835
Authors: Minggui Wang; Michelle Earley; Liang Chen; Blake M Hanson; Yunsong Yu; Zhengyin Liu; Soraya Salcedo; Eric Cober; Lanjuan Li; Souha S Kanj; Hainv Gao; Jose M Munita; Karen Ordoñez; Greg Weston; Michael J Satlin; Sandra L Valderrama-Beltrán; Kalisvar Marimuthu; Martin E Stryjewski; Lauren Komarow; Courtney Luterbach; Steve H Marshall; Susan D Rudin; Claudia Manca; David L Paterson; Jinnethe Reyes; Maria V Villegas; Scott Evans; Carol Hill; Rebekka Arias; Keri Baum; Bettina C Fries; Yohei Doi; Robin Patel; Barry N Kreiswirth; Robert A Bonomo; Henry F Chambers; Vance G Fowler; Cesar A Arias; David van Duin Journal: Lancet Infect Dis Date: 2021-11-09 Impact factor: 25.071
Authors: M Hong Nguyen; Ryan K Shields; Liang Chen; A William Pasculle; Binghua Hao; Shaoji Cheng; Jonathan Sun; Ellen G Kline; Barry N Kreiswirth; Cornelius J Clancy Journal: Clin Infect Dis Date: 2022-02-11 Impact factor: 9.079
Authors: Maria Spencer-Sandino; Roberto Riquelme-Neira; William C Shropshire; An Q Dinh; Gerardo González-Rocha; Paulina González-Muñoz; Alejandra Vera-Leiva; Rafael Araos; Blake Hanson; Cesar A Arias; José M Munita Journal: JAC Antimicrob Resist Date: 2021-06-21